Therapeutic methods in the treatment of chancroidal infections have ranged from various local measures to the parenteral administration of specific and nonspecific vaccines. Numerous authors1 have reported favorably on the results obtained with Ducrey vaccines, and for some time the intravenous administration of the specific vaccine was considered the most efficacious procedure available. Its specificity, however, was doubted by some authorities.2
The introduction of sulfanilamide was followed by encouraging reports of its action in infection due to the Ducrey bacillus. In recent reports3 the drug has been considered practically specific for this infection. However, comparative studies are few. Observation at Bellevue Hospital of 182 cases, in 114 of which sulfanilamide was given, within the past three years has enabled us to evaluate the drug from this angle and to establish therapeutic principles for the various manifestations of the disease.
In comparing the results of various treatments of chancroidal infections, the size, location and duration of the lesions, the sex, the presence of secondary infection and the variable virulence of the causative organisms are factors to be considered. In our opinion multiplicity of the
CANIZARES O, COHEN JA. TREATMENT OF CHANCROID WITH SULFANILAMIDE. Arch Derm Syphilol. 1940;42(4):649–652. doi:10.1001/archderm.1940.01490160109014
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.